Search
for
Sort by
Research 151–180 of 1000+
- Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL
- Kinase Inhibition with BAY 43–9006 in Renal Cell Carcinoma
- Outcome of long-term treatment with the 5α-reductase inhibitor finasteride in idiopathic hirsutism: clinical and hormonal effects during a 1-year course of therapy and 1-year follow-up
- Recent advances in nanocarrier-loaded gels: Which drug delivery technologies against which diseases?
- Novel Fish Oil-based Bigel System for Controlled Drug Delivery and its Influence on Immunomodulatory Activity of Imiquimod Against Skin Cancer
- Oral Testosterone With and Without Concomitant Inhibition of 5α-Reductase by Dutasteride in Hypogonadal Men for 28 Days
- COMBINATION OF AN ANTIANDROGEN AND A 5α-REDUCTASE INHIBITOR: A FURTHER STEP TOWARDS TOTAL ANDROGEN BLOCKADE?
- Dihydroartemisinin attenuates benign prostatic hyperplasia in rats by inhibiting prostatic epithelial cell proliferation
- Effects of Restraint Stress and Allopregnanolone Inhibition on Amphetamine Locomotor Sensitivity
- Repurposing Finasteride as a quorum sensing inhibitor in Pseudomonas aeruginosa
- Inhibition of the Hippo pathway by verteporfin reduces the proliferation and stemness of rat hair follicle neural crest stem cells under hypoxia
- (291) The Effect of Administration and Discontinuation of Finasteride in Male Rats
- Adverse Drug Reactions in HIV/AIDS Patients on Highly Active Antiretro Viral Therapy: A Review of Prevalence
- Sustained release of inhibitor from bionic scaffolds for wound healing and functional regeneration
- A Phase 1, Open‐Label Study of the Pharmacokinetics of Ritlecitinib in Children Aged 6–12 Years With Alopecia Areata
- A Case of Steatocystoma Multiplex in a Psoriatic Patient during Treatment with Anti-IL-12/23
- Hidradenitis suppurativa secondary to treatment with a gamma secretase inhibitor
- Pregnancy Outcomes with Paternal Exposure to Finasteride, a Synthetic 5-Alpha-Reductase Inhibitor: A Case Series
- Multidimensional assessment of adverse events of finasteride:a real-world pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS) from 2004 to April 2024
- Olumiant® (Baricitinib)-A Newly Approved Janus Kinase Inhibitor for the Treatment of Alopecia Areata.
- Dihydrotestosterone-induced hair regrowth inhibition by activating androgen receptor in C57BL6 mice simulates androgenetic alopecia
- Management of Cutaneous and Extracutaneous Side Effects of Smoothened Inhibitor Therapy for Advanced Basal Cell Carcinoma
- Improving the treatment of bacterial infections caused by multidrug-resistant bacteria through drug repositioning
- Simultaneous Target-Mediated Drug Disposition-Pharmacodynamic (TMDD-PD) Modeling of Finasteride and Dutasteride: Impact of Target Binding and Turnover on Non-linear Pharmacokinetics
- Adverse events of the thyroid peroxidase inhibitor methimazole in the treatment of hyperthyroidism: a comprehensive analysis from the first quarter of 2004 to the first quarter of 2025
- The novel drug CS-891 inhibits 5alpha-reductase activity in freshly isolated dermal papilla of human hair follicles.
- 440 Topical application of anti-cancer drug Bortezomib stimulates proliferation of follicular cells and induces expression of hair keratins via GATA-3 transcription factor
- [Therapy of androgenetic alopecia with finasteride. What must be considered in consultation and drug prescribing].
- Clinical dose ranging studies with finasteride, a type 2 5α-reductase inhibitor, in men with male pattern hair loss
- Safety and Tolerability of the Dual 5-Alpha Reductase Inhibitor Dutasteride in the Treatment of Androgenetic Alopecia